AI Article Synopsis
- Patients with peritoneal metastasis from colorectal cancer have a poor prognosis, but cytoreductive surgery is a key treatment to remove large tumors, though micrometastases often remain.
- Systemic chemotherapy is a standard treatment for these micrometastases, but intraperitoneal therapy can deliver higher doses directly to the affected area while reducing side effects.
- The review suggests more research is needed to establish the effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) combined with surgery, and explores emerging therapies like oncolytic viruses and small-molecule inhibitors for treating peritoneal metastasis.
Article Abstract
Introduction: Patients with peritoneal metastasis (PM) from colorectal cancer (CRC) typically have a poor prognosis with historically few treatment options. Cytoreductive surgery (CRS) is the mainstay of treatment to remove macrometastases into the peritoneum, but residual micrometastases are often left behind. Systemic chemotherapy remains a cornerstone of treatment for micrometastases, but intraperitoneal therapy offers advantages including higher local dose concentration with fewer systemic side effects from treatment.
Areas Covered: This review covers advancements in the routes and types of pharmacotherapies for PM in CRC.
Expert Opinion: More evidence is needed to justify HIPEC with CRS as the standard of care treatment modality for patients with resectable PM in CRC. New therapies such as oncolytic viruses, biologics, and small-molecule inhibitors may become additional treatment modalities for PM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14656566.2024.2435946 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction to: Natural compounds modulate the mechanism of action of tumour-associated macrophages against colorectal cancer: a review.
J Cancer Res Clin Oncol
December 2024
Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective.
Int J Colorectal Dis
December 2024
Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, Tamil Nadu, 603103, India.
Purpose: Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Metastatic colorectal cancer (mCRC) continues to present significant challenges, particularly in patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) tumors. This narrative review aims to provide recent developments in immunotherapy for CRC treatment, focusing on its efficacy and challenges.
View Article and Find Full Text PDFIntegrating UPLC-MS/MS Bioinformatics and In Vivo Experiments Validation to Elucidate the Mechanism of Wenzi Jiedu Decoction in Suppressing Colorectal Cancer.
Phytochem Anal
December 2024
Institute of Oncology, the First Clinical Medical College, Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Objectives: We used ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS), bioinformatics, and in vivo experiments to study the anti-colorectal cancer (CRC) effects of Wenzi Jiedu Decoction (WJD).
Methods: Detected the main components of WJD by UPLC-MS/MS. Obtained WJD targets and CRC targets through the open source database.
Distinct microbes, metabolites, and the host genome define the multi-omics profiles in right-sided and left-sided colon cancer.
Microbiome
December 2024
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: Studies have reported clinical heterogeneity between right-sided colon cancer (RCC) and left-sided colon cancer (LCC). However, none of these studies used multi-omics analysis combining genetic regulation, microbiota, and metabolites to explain the site-specific difference.
Methods: Here, 494 participants from a 16S rRNA gene sequencing cohort (50 RCC, 114 LCC, and 100 healthy controls) and a multi-omics cohort (63 RCC, 79 LCC, and 88 healthy controls) were analyzed.
Temporal trends in disability adjusted life year and mortality for colorectal cancer attributable to a high red meat diet in China from 1990 to 2021: an analysis of the global burden of disease study 2021.
BMC Gastroenterol
December 2024
Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-er-Qiao Road, Chengdu, 610072, Sichuan, P.R. China.
Background: High red meat consumption is a main modifiable risk factor for colorectal cancer mortality (CRC), but its attributable disease burden remains unclear in China. We aimed to analyze the temporal trends in CRC deaths and disability-adjusted life years (DALYs) attributable to high red meat consumption in China from 1990 to 2021 and to predict the disease burden in the next 15 years.
Methods: Data was obtained from the Global Burden of Disease (GBD) 2021 study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!